LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest

Drug resistance is a major obstacle for the successful treatment of many malignancies, including neuroblastoma, the most common extracranial solid tumor in childhood. Therefore, current attempts to improve the survival of neuroblastoma patients, as well as those with other cancers, largely depend on...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-08, Vol.8 (8), p.e72850
Main Authors: Gamell, Cristina, Schofield, Alice V, Suryadinata, Randy, Sarcevic, Boris, Bernard, Ora
Format: Article
Language:English
Subjects:
Acetylation
Antineoplastic agents
Antineoplastic Agents - pharmacology
Antineoplastic drugs
Antitumor agents
Apoptosis
Cancer
Cell adhesion & migration
Cell cycle
Cell Cycle - drug effects
Cell Line, Tumor
Chemotherapy
Children
Cytoskeleton
Deoxyribonucleic acid
DNA
DNA Damage
Drug resistance
Drug Resistance, Neoplasm - physiology
Drug therapy
Drugs
Humans
Kinases
LIM kinase
Lim Kinases - physiology
Localization
Medical research
Microtubules - metabolism
Molecular modelling
Multidrug resistance
Nerve Tissue Proteins - metabolism
Neuroblastoma
Neuroblastoma - pathology
Neuroblastoma cells
Neuroblasts
Pediatrics
Phosphorylation
Polymerization
Proteins
Sensitivity
Sensitivity enhancement
Solid tumors
Survival
Survival factor
Tubulin
Up-Regulation - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c692t-c6411eb31508c620504a87615f517ee459b3273435366e3325c8dee90492b98a3
cites cdi_FETCH-LOGICAL-c692t-c6411eb31508c620504a87615f517ee459b3273435366e3325c8dee90492b98a3
container_end_page
container_issue 8
container_start_page e72850
container_title PloS one
container_volume 8
creator Gamell, Cristina
Schofield, Alice V
Suryadinata, Randy
Sarcevic, Boris
Bernard, Ora
description Drug resistance is a major obstacle for the successful treatment of many malignancies, including neuroblastoma, the most common extracranial solid tumor in childhood. Therefore, current attempts to improve the survival of neuroblastoma patients, as well as those with other cancers, largely depend on strategies to counter cancer cell drug resistance; hence, it is critical to understand the molecular mechanisms that mediate resistance to chemotherapeutics. The levels of LIM-kinase 2 (LIMK2) are increased in neuroblastoma cells selected for their resistance to microtubule-targeted drugs, suggesting that LIMK2 might be a possible target to overcome drug resistance. Here, we report that depletion of LIMK2 sensitizes SHEP neuroblastoma cells to several microtubule-targeted drugs, and that this increased sensitivity correlates with enhanced cell cycle arrest and apoptosis. Furthermore, we show that LIMK2 modulates microtubule acetylation and the levels of tubulin Polymerization Promoting Protein 1 (TPPP1), suggesting that LIMK2 may participate in the mitotic block induced by microtubule-targeted drugs through regulation of the microtubule network. Moreover, LIMK2-depleted cells also show an increased sensitivity to certain DNA-damage agents, suggesting that LIMK2 might act as a general pro-survival factor. Our results highlight the exciting possibility of combining specific LIMK2 inhibitors with anticancer drugs in the treatment of multi-drug resistant cancers.
doi_str_mv 10.1371/journal.pone.0072850
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1430787155</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478185988</galeid><doaj_id>oai_doaj_org_article_9231522d18974441b948f27aea372372</doaj_id><sourcerecordid>A478185988</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-c6411eb31508c620504a87615f517ee459b3273435366e3325c8dee90492b98a3</originalsourceid><addsrcrecordid>eNqNkl2L1DAYhYso7jr6D0QLguDFjM1Xk9wIy-LH4MiCX7chTd-2WTrNmKTiXvnXzcx0lykoSEtT0uecvD2cLHuKihUiHL2-dqMfdL_auQFWRcGxYMW97BxJgpclLsj9k_ez7FEI10XBiCjLh9kZJlIixMR59nuz_vQR51uorY4Qcg_BhqgHA3l0uelg62IHXu9gjNbktR_bkNshH2D0rup1iG6rcwN9H_LYeTe2XfJox15H64bcNQfJ0g71aKA-gLm5MT3k2qez4uPsQaP7AE-mdZF9e_f26-WH5ebq_fryYrM0pcQxPSlCUBHECmHSH7GCasFLxBqGOABlsiKYE0oYKUsgBDMjagBZUIkrKTRZZM-PvrveBTVlFxSipOCCI8YSsT4StdPXauftVvsb5bRVhw3nW6V9yqAHJXEaBOMaCckppaiSVDSYa9CE4_29yN5Mp41VitbAEL3uZ6bzL4PtVOt-KsKpRCVPBi8mA-9-jCmnf4w8Ua1OU9mhccnMbG0w6oJygQSTQiRq9RcqXTVsrUntaWzanwlezQSJifArtnoMQa2_fP5_9ur7nH15wnag-9gF14_7poQ5SI-g8S4ED81dcqhQ-_LfpqH25VdT-ZPs2Wnqd6LbtpM_9LH_Eg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1430787155</pqid></control><display><type>article</type><title>LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Gamell, Cristina ; Schofield, Alice V ; Suryadinata, Randy ; Sarcevic, Boris ; Bernard, Ora</creator><contributor>Belkhiri, Abbes</contributor><creatorcontrib>Gamell, Cristina ; Schofield, Alice V ; Suryadinata, Randy ; Sarcevic, Boris ; Bernard, Ora ; Belkhiri, Abbes</creatorcontrib><description>Drug resistance is a major obstacle for the successful treatment of many malignancies, including neuroblastoma, the most common extracranial solid tumor in childhood. Therefore, current attempts to improve the survival of neuroblastoma patients, as well as those with other cancers, largely depend on strategies to counter cancer cell drug resistance; hence, it is critical to understand the molecular mechanisms that mediate resistance to chemotherapeutics. The levels of LIM-kinase 2 (LIMK2) are increased in neuroblastoma cells selected for their resistance to microtubule-targeted drugs, suggesting that LIMK2 might be a possible target to overcome drug resistance. Here, we report that depletion of LIMK2 sensitizes SHEP neuroblastoma cells to several microtubule-targeted drugs, and that this increased sensitivity correlates with enhanced cell cycle arrest and apoptosis. Furthermore, we show that LIMK2 modulates microtubule acetylation and the levels of tubulin Polymerization Promoting Protein 1 (TPPP1), suggesting that LIMK2 may participate in the mitotic block induced by microtubule-targeted drugs through regulation of the microtubule network. Moreover, LIMK2-depleted cells also show an increased sensitivity to certain DNA-damage agents, suggesting that LIMK2 might act as a general pro-survival factor. Our results highlight the exciting possibility of combining specific LIMK2 inhibitors with anticancer drugs in the treatment of multi-drug resistant cancers.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0072850</identifier><identifier>PMID: 23991158</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Acetylation ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Antineoplastic drugs ; Antitumor agents ; Apoptosis ; Cancer ; Cell adhesion &amp; migration ; Cell cycle ; Cell Cycle - drug effects ; Cell Line, Tumor ; Chemotherapy ; Children ; Cytoskeleton ; Deoxyribonucleic acid ; DNA ; DNA Damage ; Drug resistance ; Drug Resistance, Neoplasm - physiology ; Drug therapy ; Drugs ; Humans ; Kinases ; LIM kinase ; Lim Kinases - physiology ; Localization ; Medical research ; Microtubules - metabolism ; Molecular modelling ; Multidrug resistance ; Nerve Tissue Proteins - metabolism ; Neuroblastoma ; Neuroblastoma - pathology ; Neuroblastoma cells ; Neuroblasts ; Pediatrics ; Phosphorylation ; Polymerization ; Proteins ; Sensitivity ; Sensitivity enhancement ; Solid tumors ; Survival ; Survival factor ; Tubulin ; Up-Regulation - drug effects</subject><ispartof>PloS one, 2013-08, Vol.8 (8), p.e72850</ispartof><rights>COPYRIGHT 2013 Public Library of Science</rights><rights>2013 Gamell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Gamell et al 2013 Gamell et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-c6411eb31508c620504a87615f517ee459b3273435366e3325c8dee90492b98a3</citedby><cites>FETCH-LOGICAL-c692t-c6411eb31508c620504a87615f517ee459b3273435366e3325c8dee90492b98a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1430787155/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1430787155?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23991158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Belkhiri, Abbes</contributor><creatorcontrib>Gamell, Cristina</creatorcontrib><creatorcontrib>Schofield, Alice V</creatorcontrib><creatorcontrib>Suryadinata, Randy</creatorcontrib><creatorcontrib>Sarcevic, Boris</creatorcontrib><creatorcontrib>Bernard, Ora</creatorcontrib><title>LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Drug resistance is a major obstacle for the successful treatment of many malignancies, including neuroblastoma, the most common extracranial solid tumor in childhood. Therefore, current attempts to improve the survival of neuroblastoma patients, as well as those with other cancers, largely depend on strategies to counter cancer cell drug resistance; hence, it is critical to understand the molecular mechanisms that mediate resistance to chemotherapeutics. The levels of LIM-kinase 2 (LIMK2) are increased in neuroblastoma cells selected for their resistance to microtubule-targeted drugs, suggesting that LIMK2 might be a possible target to overcome drug resistance. Here, we report that depletion of LIMK2 sensitizes SHEP neuroblastoma cells to several microtubule-targeted drugs, and that this increased sensitivity correlates with enhanced cell cycle arrest and apoptosis. Furthermore, we show that LIMK2 modulates microtubule acetylation and the levels of tubulin Polymerization Promoting Protein 1 (TPPP1), suggesting that LIMK2 may participate in the mitotic block induced by microtubule-targeted drugs through regulation of the microtubule network. Moreover, LIMK2-depleted cells also show an increased sensitivity to certain DNA-damage agents, suggesting that LIMK2 might act as a general pro-survival factor. Our results highlight the exciting possibility of combining specific LIMK2 inhibitors with anticancer drugs in the treatment of multi-drug resistant cancers.</description><subject>Acetylation</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cell adhesion &amp; migration</subject><subject>Cell cycle</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Line, Tumor</subject><subject>Chemotherapy</subject><subject>Children</subject><subject>Cytoskeleton</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA Damage</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - physiology</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Humans</subject><subject>Kinases</subject><subject>LIM kinase</subject><subject>Lim Kinases - physiology</subject><subject>Localization</subject><subject>Medical research</subject><subject>Microtubules - metabolism</subject><subject>Molecular modelling</subject><subject>Multidrug resistance</subject><subject>Nerve Tissue Proteins - metabolism</subject><subject>Neuroblastoma</subject><subject>Neuroblastoma - pathology</subject><subject>Neuroblastoma cells</subject><subject>Neuroblasts</subject><subject>Pediatrics</subject><subject>Phosphorylation</subject><subject>Polymerization</subject><subject>Proteins</subject><subject>Sensitivity</subject><subject>Sensitivity enhancement</subject><subject>Solid tumors</subject><subject>Survival</subject><subject>Survival factor</subject><subject>Tubulin</subject><subject>Up-Regulation - drug effects</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl2L1DAYhYso7jr6D0QLguDFjM1Xk9wIy-LH4MiCX7chTd-2WTrNmKTiXvnXzcx0lykoSEtT0uecvD2cLHuKihUiHL2-dqMfdL_auQFWRcGxYMW97BxJgpclLsj9k_ez7FEI10XBiCjLh9kZJlIixMR59nuz_vQR51uorY4Qcg_BhqgHA3l0uelg62IHXu9gjNbktR_bkNshH2D0rup1iG6rcwN9H_LYeTe2XfJox15H64bcNQfJ0g71aKA-gLm5MT3k2qez4uPsQaP7AE-mdZF9e_f26-WH5ebq_fryYrM0pcQxPSlCUBHECmHSH7GCasFLxBqGOABlsiKYE0oYKUsgBDMjagBZUIkrKTRZZM-PvrveBTVlFxSipOCCI8YSsT4StdPXauftVvsb5bRVhw3nW6V9yqAHJXEaBOMaCckppaiSVDSYa9CE4_29yN5Mp41VitbAEL3uZ6bzL4PtVOt-KsKpRCVPBi8mA-9-jCmnf4w8Ua1OU9mhccnMbG0w6oJygQSTQiRq9RcqXTVsrUntaWzanwlezQSJifArtnoMQa2_fP5_9ur7nH15wnag-9gF14_7poQ5SI-g8S4ED81dcqhQ-_LfpqH25VdT-ZPs2Wnqd6LbtpM_9LH_Eg</recordid><startdate>20130821</startdate><enddate>20130821</enddate><creator>Gamell, Cristina</creator><creator>Schofield, Alice V</creator><creator>Suryadinata, Randy</creator><creator>Sarcevic, Boris</creator><creator>Bernard, Ora</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20130821</creationdate><title>LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest</title><author>Gamell, Cristina ; Schofield, Alice V ; Suryadinata, Randy ; Sarcevic, Boris ; Bernard, Ora</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-c6411eb31508c620504a87615f517ee459b3273435366e3325c8dee90492b98a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acetylation</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cell adhesion &amp; migration</topic><topic>Cell cycle</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Line, Tumor</topic><topic>Chemotherapy</topic><topic>Children</topic><topic>Cytoskeleton</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA Damage</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - physiology</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Humans</topic><topic>Kinases</topic><topic>LIM kinase</topic><topic>Lim Kinases - physiology</topic><topic>Localization</topic><topic>Medical research</topic><topic>Microtubules - metabolism</topic><topic>Molecular modelling</topic><topic>Multidrug resistance</topic><topic>Nerve Tissue Proteins - metabolism</topic><topic>Neuroblastoma</topic><topic>Neuroblastoma - pathology</topic><topic>Neuroblastoma cells</topic><topic>Neuroblasts</topic><topic>Pediatrics</topic><topic>Phosphorylation</topic><topic>Polymerization</topic><topic>Proteins</topic><topic>Sensitivity</topic><topic>Sensitivity enhancement</topic><topic>Solid tumors</topic><topic>Survival</topic><topic>Survival factor</topic><topic>Tubulin</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gamell, Cristina</creatorcontrib><creatorcontrib>Schofield, Alice V</creatorcontrib><creatorcontrib>Suryadinata, Randy</creatorcontrib><creatorcontrib>Sarcevic, Boris</creatorcontrib><creatorcontrib>Bernard, Ora</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gamell, Cristina</au><au>Schofield, Alice V</au><au>Suryadinata, Randy</au><au>Sarcevic, Boris</au><au>Bernard, Ora</au><au>Belkhiri, Abbes</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2013-08-21</date><risdate>2013</risdate><volume>8</volume><issue>8</issue><spage>e72850</spage><pages>e72850-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Drug resistance is a major obstacle for the successful treatment of many malignancies, including neuroblastoma, the most common extracranial solid tumor in childhood. Therefore, current attempts to improve the survival of neuroblastoma patients, as well as those with other cancers, largely depend on strategies to counter cancer cell drug resistance; hence, it is critical to understand the molecular mechanisms that mediate resistance to chemotherapeutics. The levels of LIM-kinase 2 (LIMK2) are increased in neuroblastoma cells selected for their resistance to microtubule-targeted drugs, suggesting that LIMK2 might be a possible target to overcome drug resistance. Here, we report that depletion of LIMK2 sensitizes SHEP neuroblastoma cells to several microtubule-targeted drugs, and that this increased sensitivity correlates with enhanced cell cycle arrest and apoptosis. Furthermore, we show that LIMK2 modulates microtubule acetylation and the levels of tubulin Polymerization Promoting Protein 1 (TPPP1), suggesting that LIMK2 may participate in the mitotic block induced by microtubule-targeted drugs through regulation of the microtubule network. Moreover, LIMK2-depleted cells also show an increased sensitivity to certain DNA-damage agents, suggesting that LIMK2 might act as a general pro-survival factor. Our results highlight the exciting possibility of combining specific LIMK2 inhibitors with anticancer drugs in the treatment of multi-drug resistant cancers.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>23991158</pmid><doi>10.1371/journal.pone.0072850</doi><tpages>e72850</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2013-08, Vol.8 (8), p.e72850
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1430787155
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central
subjects Acetylation
Antineoplastic agents
Antineoplastic Agents - pharmacology
Antineoplastic drugs
Antitumor agents
Apoptosis
Cancer
Cell adhesion & migration
Cell cycle
Cell Cycle - drug effects
Cell Line, Tumor
Chemotherapy
Children
Cytoskeleton
Deoxyribonucleic acid
DNA
DNA Damage
Drug resistance
Drug Resistance, Neoplasm - physiology
Drug therapy
Drugs
Humans
Kinases
LIM kinase
Lim Kinases - physiology
Localization
Medical research
Microtubules - metabolism
Molecular modelling
Multidrug resistance
Nerve Tissue Proteins - metabolism
Neuroblastoma
Neuroblastoma - pathology
Neuroblastoma cells
Neuroblasts
Pediatrics
Phosphorylation
Polymerization
Proteins
Sensitivity
Sensitivity enhancement
Solid tumors
Survival
Survival factor
Tubulin
Up-Regulation - drug effects
title LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A52%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LIMK2%20mediates%20resistance%20to%20chemotherapeutic%20drugs%20in%20neuroblastoma%20cells%20through%20regulation%20of%20drug-induced%20cell%20cycle%20arrest&rft.jtitle=PloS%20one&rft.au=Gamell,%20Cristina&rft.date=2013-08-21&rft.volume=8&rft.issue=8&rft.spage=e72850&rft.pages=e72850-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0072850&rft_dat=%3Cgale_plos_%3EA478185988%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-c6411eb31508c620504a87615f517ee459b3273435366e3325c8dee90492b98a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1430787155&rft_id=info:pmid/23991158&rft_galeid=A478185988&rfr_iscdi=true